Healthcare / BiotechnologyNasdaqCM
$1.25
+0.07 (+5.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-24.6M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$112M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-68.5%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-23.5M · FCF $-24.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-23.5M | $-23.5M | $-34.0M | $-25.8M | $-21.4M | $-11.7M | $-7.8M |
| EBITDA | $-23.2M | $-23.2M | $-33.7M | $-25.5M | $-21.1M | $-28.5M | $-17.3M |
| EPS | -0.32 | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 | -23.76 |
| Balance Sheet | |||||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.05 | 0.04 | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-24.6M | $-24.6M | $-28.5M | $-16.2M | $-18.7M | $-3.7M | $-3.4M |
| Returns | |||||||
| ROE | -68.5% | -68.5% | -181.2% | -105.4% | -53.2% | -22.9% | 11.5% |
| Valuation | |||||||
| P/B | 2.65 | 2.65 | 1.60 | 2.37 | 1.33 | — | — |
| Growth & Yield | |||||||
| EPS Growth | 62.8% | 62.8% | 0.0% | 5.5% | — | 86.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+423.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.86 → -0.32
Residual
+423.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.